Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics.
OBJECTIVE
To estimate the α/β ratio of prostate cancer treated with external beam radiation only by use of a model of long-term prostate-specific antigen (PSA) dynamics.


METHODS
Repeated measures of PSA from 5,093 patients from 6 institutions treated for localized prostate cancer by external beam radiation therapy (EBRT) without planned androgen deprivation were analyzed. A biphasic linear mixed model described the post-treatment evolution of PSA, rather than a conventional model of time to biochemical recurrence. The model was adjusted for standard prognostic factors (T stage, initial PSA level, and Gleason score) and cohort-specific effects. The radiation dose fractionation effect was estimated from the long-term rate of rise of PSA level.


RESULTS
Adjusted for other factors, total dose of EBRT and sum of squared doses per fraction were associated with long-term rate of change of PSA level (p = 0.0017 and p = 0.0003, respectively), an increase of each being associated with a lower rate of rise. The α/β ratio was estimated at 1.55 Gy (95% confidence band, 0.46-4.52 Gy). This estimate was robust to adjustment of the linear mixed model.


CONCLUSIONS
By analysis of a large EBRT-only cohort along with a method that uses all the repeated measures of PSA after the end of treatment, a low and precise α/β was estimated. These data support the use of hypofractionation at fractional doses up to 2.8 Gy but cannot presently be assumed to accurately represent higher doses per fraction.
Proust-Lima
Cécile
C
INSERM, U897, Epidemiology and Biostatistics Research Center, Bordeaux, France. scott.williams@petermac.org
Taylor
Jeremy M G
JM
Sécher
Solène
S
Sandler
Howard
H
Kestin
Larry
L
Pickles
Tom
T
Bae
Kyoungwha
K
Allison
Roger
R
Williams
Scott
S
D000368:Aged; D015331:Cohort Studies; D019583:Dose Fractionation, Radiation; D006801:Humans; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000532:radiotherapy*; D011836:Radiation Tolerance; D018709:Statistics, Nonparametric
D017430:Prostate-Specific Antigen
Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1254-9
14630259
Semin Radiat Oncol. 2008 Oct;18(4):234-9
18725109
Radiother Oncol. 2005 Jul;76(1):1-3
15990189
Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1463-8
16169683
Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1093-104
12829147
Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):1021-31
11429230
Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):912-4
14575821
Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1082-7
15519778
J Clin Oncol. 2005 Feb 1;23(4):816-25
15681526
Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):6-13
11777617
Cancer. 1999 Oct 15;86(8):1557-66
10526285
Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
16798415
Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1072-83
16965866
Biometrics. 1982 Dec;38(4):963-74
7168798
Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):24-33
17448868
Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1351-6
15590164
Clin Oncol (R Coll Radiol). 2007 Jun;19(5):289-301
17517328
Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):194-203
12504054
Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1095-101
10192361
Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):782-91
19014779